Programme Changes

The organisers do not assume liability for any changes in the programme due to external or unforeseen circumstances.
The CONGRESS REGISTRATION DESK will operate the following hours:

- **Friday, 9th Sept.** 16:00 – 18:00
- **Saturday, 10th Sept.** 07:00 – 19:30
- **Sunday, 11th Sept.** 06:30 – 18:00
- **Monday, 12th Sept.** 06:30 – 17:30
- **Tuesday, 13th Sept.** 07:45 – 14:00

**COMMERCIAL EXHIBITION Opening times**

- **Saturday, 10th Sept.** 10:00 – 18:00
- **Sunday, 11th Sept.** 07:00 – 18:00
- **Monday, 12th Sept.** 07:00 – 17:00
- **Tuesday, 13th Sept.** 08:30 – 12:30

**Media Check Opening times**

- **Saturday, 10th Sept.** 07:00 – 18:15
- **Sunday, 11th Sept.** 06:30 – 18:00
- **Monday, 12th Sept.** 06:30 – 17:30
- **Tuesday, 13th Sept.** 07:45 – 12:00

The 44th Annual Meeting of the European Thyroid Association has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 19 European CME credits (ECMEC®s).
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
</tr>
</thead>
</table>
| 08.30 | Reference systems for thyroid functions tests (the IFCC standardization committee)  
Katleen Van Uytfanghe (Belgium) |
| 09.00 | Pitfalls in the measurement of thyroid function tests including how FT4, FT3 are measured, interference due to pregnancy, biotin, heterophilic antibodies, thyroid hormone binding protein abnormalities etc.  
Mark Gurnell (United Kingdom) |
| 09.30 | Discrepant results in thyroid function tests (including resistance to thyroid hormones, TSH-omas, secondary hypothyroidism)  
Luca Persani (Italy) |
| 10.00 | General discussion |
| 10.20 | Coffee Break |
|       | Session 2                                                                 |
| 10.40 | Genetic basis of thyroid function or Genomic variants which determine TSH setpoint throughout life  
Marco Medici (Netherlands) |
| 11.10 | The pituitary/thyroid axis and inflammation; what the COVID-19 pandemic has taught us  
Ilaria Muller (Italy) |
| 11.40 | The pros and cons of measuring autoantibodies to TPO and TG  
Methodology, including prevalence, and methods of thyroid autoantibodies measurements  
Sofie Bliddal (Denmark) |
| 11.55 | Autoimmune considerations  
Gerasimos Sykiotis (Switzerland) |
| 12.10 | General discussion |
| 12.30 | CLOSE |
BASIC Update

Thyroid Hormone Action in health and disease or Thyroid Hormones from Synthesis to Tissue-specific Action

Chairs: Lars Moeller, Germany and Marian Ludgate, United Kingdom

09.00 Correlating thyroid development with function
Sabine Costagliola (Belgium)

09.30 Update on thyroid hormone transporters
Stefan Groeneweg (Netherlands)

10.00 Visualizing TR action, mouse models of tissue specific TH action
Balázs Gereben (Hungary)

10.30 General discussion

10.50 Coffee Break

Chairs: Malgorzata Oczko-Wojciechowska, Poland and Edward Visser, Netherlands

11.10 TH action in the innate immune system
Anne van der Spek (Netherlands)

11.40 Deiodinases, peripheral regulators of TH action
Domenico Salvatore (Italy)

12.10 Differing roles for thyroid hormone receptor isoforms in pituitary feedback
Lars Moeller (Germany)

12.40 General discussion

13.00 CLOSE

SATURDAY
10.09.2022
09.00 - 13.00
08.00  **WELCOME**
Laura Fugazzola, Italy

**SESSION I  News from the bench side**
Chairs: Clara Alvarez (Spain) and Miguel Melo (Portugal)

08.20  Tumor-related inflammation and thyroid cancer: friends or foes?
Romana Netea-Maier (The Netherlands)

08.40  Thyroid cancer genotyping in Europe
Dagmar Führer-Sakel (Germany)

09.00  Involvement of immortalization mechanisms in thyroid cancer
Paula Soares (Portugal)

**SESSION II  News from the clinics**
Chairs: Maria Grazia Castagna (Italy) and Agnieszka Czarniecka (Poland)

09.20  Central lymph node compartment dissection: yes, no, selective?
Madelon Metman (The Netherlands)

09.40  PET/CT-metrics and radiomics in thyroid nodules
Luca Giovanella (Switzerland)

10.00  Radioiodine in patients with low risk thyroid cancer
Sophie Leboulleux (Switzerland)

10.20  Coffee Break

**SESSION III  LECTURE**
Chair: Rossella Elisei (Italy)

11.00  Genomic alterations in thyroid cancers: biological and clinical insights
Inigo Landa (USA)

**SESSION IV  Hands on the patient**
Chairs: Thera Links (The Netherlands), Barbara Jarzab (Poland)

11.30  Management of nodules in children
Hanneke Van Santen (The Netherlands)

11.50  Difficult cases, sliding doors:
FOCUS 1: Differentiated thyroid cancer  Simone De Leo (Italy)
FOCUS 2: Medullary thyroid cancer  Jolanta Krajewska (Poland)

12.30  General Assembly ETA Cancer Group
with election of the new leader group
Clara Alvarez (Spain)

12.45  CLOSING REMARKS
SESSION I

08.00  Registration and Coffee /Tea
08.25  INTRODUCTION
Rodrigo Moreno-Reyes (Belgium)
Chairs: Effie Koukkou (Greece), Lluis Vila (Spain)
08.30  The rise in plant-based diets: a concern for iodine intake? 
Sarah Bath (United Kingdom)
08.50  Iodine supplementation in pregnancy 
– what is the evidence in mild-to-moderate 
iodine deficiency? 
Mariana Dineva (United Kingdom)
09.10  Beyond the median in UIC studies: where we stand now 
Maria Andersson (Switzerland)
09.30  Current Iodine status in Norway 
Lisbeth Dahl (Norway)
09.50  Coffee/Tea and Posters  🍵

SESSION II

Chairs: Mafalda Marcelino (Portugal), Helena Filipsson Nyström (Sweden)
10.30  Iodine status in the WHO European Region 
– opportunities and challenges 
Phyo Pyi Pyi (WHO, Europe)
10.50  Iodine status among various population groups in Belgium: 
An update and future steps 
Stefanie Vandevijvere (Belgium)
11.10  Selective approach to optimize iodine intake in Belgium 
Laurence Doughan (Belgium)
11.30  Iodine status: an overview of situation and 
measures in Switzerland 
Clara Benzi Schmid (Switzerland)
11.50  Iodine status and recommendations in Finland 
Iris Erlund (Finland)
12.15  LUNCH and CLOSE
BASIC COURSE IN DIAGNOSTIC THYROID ULTRASOUND

Chairs: Cosimo Durante (Italy), Gilles Russ (France)

08.00  **Kickoff event**
The kickoff event introduces the course goals and the agenda.
Cosimo Durante
Duration: 30 min

**Activity #1**
- A presenting author introducing clinical cases (6 to 9) and asking questions
  Cosimo Durante
- Audience televoting on questions
- Expert panels reacting to the answers
  Eva Gentbrugge, Enrico Papini, Gilles Russ, Tamás Solymosi, Nunzia Tacelli, Annick Van den Bruel
- Take home messages
  Cosimo Durante

10.15 - 11.15 Coffee Break

**Activity #2**
- Clinical cases in small subgroups with a tutor
- Then all subgroups join and one member of each subgroup presents the case to the whole group with an expert facilitating the discussion
- Take home messages

**Hands-on sonography training**
Real-time ultrasound examinations will be performed on patient volunteers
Tutor: Cosimo Durante, Eva Gentbrugge, Bruno Lapauw, Enrico Papini, Steven Raeymaeckers, Gilles Russ, Tamás Solymosi, Nunzia Tacelli, Annick Van den Bruel
Duration: 90 min

13.00  **Close**
All participants who have successfully completed the course will receive a “Certificate of attendance” issued by the European Thyroid Association
13:45 – 14:00  Room
OPENING Ceremony

Chairs: Kris Poppe (Belgium) and Graham Richard Williams (United Kingdom)

14:00 - 15:30  Room
ORAL Session 1: Topic Highlights

Chairs: Kris Poppe (Belgium) and Graham Richard Williams (United Kingdom)

14:00 - 14:15  OP-01-01
Cryo-electron Microscopy Structure of Full length TSH Receptor in Complex with TSH Receptor Blocking Human Monoclonal Autoantibody K1-70TM
Ricardo Nunez Miguel (United Kingdom)

14:15 - 14:30  OP-01-02
A randomized, double-blind, placebo-controlled trial of vitamin D supplementation in patients newly diagnosed with Graves’ disease
Diana Grove-Laugesen (Denmark)

14:30 - 14:45  OP-01-03
The relationship between thyroid function and lipid metabolomics and response to combination thyroid hormone replacement
Peter Taylor (United Kingdom)

14:45 - 15:00  OP-01-04
Selenoprotein deficiency disorder predisposes to aortic aneurysm formation
Erik Schoenmakers (Belgium)

15:00 - 15:15  OP-01-05
Sarcopenia as a prognostic factor in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors
Cristina Dalmiglio (Italy)

15:15 - 15:30  OP-01-06
Modeling Braf-induced thyroid cancer development and cell redifferentiation using pluripotent stem cell-derived organoids
Mirian Romitti (Belgium)
15:30 - 16:30  Room SALLE M
SATellite Symposium 1
Making treatment decisions for thyroid cancers with oncogenic drivers

16:30 - 17:30  Room POSTER HALL
POSTer Session 1
PS1-01-01– 09 COVID & thyroid disease  
Chair: Kristien Boelaert (United Kingdom)
PS1-02-10 – 18 Hypothyroidism  
Chair: Helena Filipsson Nyström (Sweden)
PS1-03-19 – 28 Thyroid Cancer Clinical 1  
Chair: Barbara Jarzab (Poland)
PS1-04-29 – 36 Thyroid hormone transporters and development  
Chair: Ricardo Zucchi (Italy)
PS1-05-37 – 46 Miscellaneous  
Chair: Peter Kopp (Switzerland)

17:30 - 18:30  Room HENRY LE BOEUF
A Year in...  
Chairs: Paula Soares (Portugal) and Bijay Vaidya (United Kingdom)
17:30 - 17:50 A Year in Clinical Thyroidology  
Robin Peeters (Netherlands)
17:50 - 18:10 A Year in Basic Thyroidology  
Lars Christian Moeller (Germany)
18:10 - 18:30 A Year in Thyroid Cancer  
Barbara Jarzab (Poland)

SATURDAY
10.09.2022
18:30 - 19:00
HENRY LE BOEUF
HISTORICAL Vignette
Chair: Graham Richard Williams (United Kingdom)
The story of TSH assays through the ages
Josef Köhrle (Germany)

19:00 - 19:30
HENRY LE BOEUF
ETJ Lecture
Chair: Simon Pearce (United Kingdom)
Thyroid hormone as a temporal switch in vertebrates development
Frédéric Flamant (France)
07:00 - 08:00  Room STUDIO
SATTELITE SYMPOSIUM 2
Thyroid Eye Disease: Addressing the Need for Early Intervention and Comanagement

08:00 - 09:30  Room HENRY LE BOEUF
SCIENTIFIC SYMPOSIUM 1
MANAGEMENT of the thyroid nodule
Chairs: Rossella Elisai (Italy) and Bernard Corvilain (Belgium)
08:00 - 08:25  Construction of an international thyroid nodule risk stratification system (I-TIRADS)
Laszlo Hegedüs (Denmark)
08:30 - 08:55  Is the thyroid scintigraphy still relevant in the era EU-TIRADS, fine needle aspiration and molecular testing?
Aglaia Kyrilli (Belgium)
09:00 - 09:25  ETA 2022 Thyroid nodule management guideline
Cosimo Durante (Italy)

08:00 - 09:30  Room SALLE M
SCIENTIFIC SYMPOSIUM 2
MECHANISTICAL insights into thyroid cancer progression
Chair: Clara Alvarez (Spain) and Maria Alevizaki (Greece)
08:00 - 08:30  Senescence in thyroid cancer
Angela Greco (Italy)
08:30 - 09:00  Organoid approaches to thyroid cancer treatment evaluation
Luc Sondorp (Netherlands)
09:00 - 09:30  Single-cell transcriptomics in thyroid cancer
Vincent Detours (Belgium)
10:00 - 11:00

**Room SALLE M**

**ORAL SESSION 2**

**PREGNANCY**

Chairs: Kristin Bolaert (United Kingdom) and Brigitte Decallone (Belgium)

10:00 - 10:12  **OP-02-07**
Use of levothyroxine for euthyroid women with positive thyroid antibodies and infertility: results of thesis (treatment of hypothyroidism in europe by specialists: an international survey)
Roberto Negro (Italy)

10:12 - 10:24  **OP-02-08**
Real world study on the impact of thyroid hormone treatment on pregnancy outcomes in women with subclinical hypothyroidism without TPOAb
Georgiana Sitoris (Belgium)

10:24 - 10:36  **OP-02-09**
Hypothyroidism and the risk of preeclampsia: a national and regional study of 1,014,775 pregnancies in Denmark
Stine Linding Andersen (Denmark)

10:36 - 10:48  **OP-02-10**
Phthalate exposure is associated with thyroid function during pregnancy through a novel pathway as a hCG disruptor
Arash Derakhshan (Netherlands)

10:48 - 11:00  **OP-02-11**
Association of Thyroid Function and TPOAb Positivity with the Risk of Postpartum Depression: a population-based cohort study, systematic review, and meta-analysis
Federica Sileo (Italy)
10:00 - 11:00

ORAL Session 3

ADVANCED thyroid cancer
Chairs: Sophie Leboulleux (Switzerland) and Annick Van Den Bruel (Belgium)

10:00 - 10:12  OP-03-12
Clinicopathological and epidemiological features of thyroid cancer patients intended to initiate systemic therapy
Elisa Minaldi (Italy)

10:12 - 10:24  OP-03-13
Thyroid cancer relapse as a challenge to a surgeon: the efficacy of radioguided occult lesion localization (ROLL) technique
Agnieszka Czarniecka (Poland)

10:24 - 10:36  OP-03-14
Entrectinib in patients with NTRK fusion-positive (NTRK-fp) thyroid cancer: updated data from STARTRK-2
Daniel W Bowles (United States)

10:36 - 10:48  OP-03-15
Assessment of adrenal function in a large series of patients confirms that adrenal insufficiency is a common cause of fatigue during treatment with multikinase inhibitors (MKIs)
Carla Colombo (Italy)

10:48 - 11:00  OP-03-16
A clinical and molecular study of a real-world cohort of BRAF V600E anaplastic thyroid carcinoma treated with Dabrafenib and Trametinib
Tiago Nunes da Silva (Portugal)
11:00 - 12:00  
HENRY LE BOEUF  
Room  
**SATELLITE Symposium 3**  
**T3 for HYPOThYROIDISM**

12:00 - 13:00  
**POSTER HALL**  
**POSTER Session 2**

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS2-06-47 – 56 Hypothyroidism treatment</td>
<td>Allan Carle (Denmark)</td>
</tr>
<tr>
<td>PS2-07-57 – 66 Graves’ Disease 1</td>
<td>Milos Zarkovic (Serbia)</td>
</tr>
<tr>
<td>PS2-08-67 – 76 Thyroid Cancer Basic</td>
<td>Clara Alvarez (Spain)</td>
</tr>
<tr>
<td>PS2-09-77 – 86 Thyroid Hormone Action</td>
<td>Robert Opitz (Germany)</td>
</tr>
<tr>
<td>PS2-10-87 – 96 Nodules &amp; cancer</td>
<td>Furio Pacini (Italy)</td>
</tr>
</tbody>
</table>

12:00 - 13:00  
**SALLE M**  
**SATELLITE Symposium 4**

WHERE DOES the balance lie in achieving good clinical outcomes and quality of life in RAI-R DTC?
13:00 - 13:45
Meet the EXPERT

**1**
**Thyroid and male reproductive organs**
David Unuane (Belgium)

13:00 - 13:45
Meet the EXPERT

**2**
**Deiodinase measurements: how, when, why?**
Anita Boelen (Netherlands)

13:00 - 13:45
Meet the EXPERT

**3**
**Mendelian randomisation methods and applications**
Peter Taylor (United Kingdom)

13:00 - 13:45
Meet the EXPERT

**4**
**New anaplastic thyroid cancer guidelines**
Katie Newbold (United Kingdom)
13:45 - 14:45  Room SALLE M

**ORAL Session 4**

**BASIC 1**

Chairs: Duncan Bassett (United Kingdom) and Xavier De Deeken (Belgium)

13:45 - 13:57  **OP-04-17**
Age and diet regulate intrahepatic thyroid hormone concentration in a mouse model of Non-Alcoholic Fatty Liver Disease (NAFLD)
Eveline Bruinstroop (Netherlands)

13:57 - 14:09  **OP-04-18**
Differential impact of intrathyroidal IL-4 expression on thyroiditis development in C57BL/6j and NOD.H2h4 Thy-IL4 mice
Karima Merakchii (Belgium)

14:09 - 14:21  **OP-04-19**
A thyroid hormone-independent role for transthyretin in neural stem cells of the postnatal mouse subventricular zone?
Pieter Vancamp (France)

14:21 - 14:33  **OP-04-20**
Rewiring of liver diurnal transcriptome rhythms by triiodothyronine (T3) supplementation
Leonardo de Assis (Germany)

14:33 - 14:45  **OP-04-21**
Cryo-Electron Microscopy Structures of Human Thyroid Peroxidase (TPO) in complex with TPO antibodies
Ricardo Nunez Miguel (United Kingdom)

SUNDAY 11.09.2022
13:45 - 14:45 HENRY LE BOEUF

ORAL Session 5

AUTOIMMUNITY

Chairs: Alessandro Antonelli (Italy) and Damien Gruson (Belgium)

13:45 - 13:57  
OP-05-22  
Update on the role of caveolin-1 in cell homeostasis and oxidative stress in Hashimoto’s thyroiditis and Graves’ disease  
Marie-Christine Many (Belgium)

13:57 - 14:09  
OP-05-23  
Cut-offs for thyroid peroxidase and thyroglobulin antibodies in early pregnancy are not similar and may differ from non-pregnant individuals: evidence from 10,905 Danish pregnant women  
Stine Linding Andersen (Denmark)

14:09 - 14:21  
OP-05-24  
Sirolimus for Graves’ Orbitopathy: a novel drug for the management of patients with moderate-to-severe Graves’ Orbitopathy?  
Giulia Lanzolla (Italy)

14:21 - 14:33  
OP-05-25  
Intestinal barrier permeability in patients with Hashimoto’s thyroiditis associated to non-endocrine autoimmune disorders  
Camilla Virili (Italy)

14:33 - 14:45  
OP-05-26  
Prospective Single Blind, USA-Based, Multicenter Comparison of TSH-Receptor Antibody Immunoassays  
Mark Lupo (United States)
15:00 - 16:00  
**Room SALLE M**

**SATELLITE Symposium 5**

**NEW DIRECTIONS** in thyroid cancer: Treatment sequencing - with interactive tumour board

---

16:00 - 17:30  
**Room HENRY LE BOEUF**

**SCIENTIFIC Symposium 3**

**TRANSCRIPTOME** responses to thyroid hormone in T3 target tissues  
Chairs: Domenico Salvatore (Italy) and Peter Kopp (Switzerland)

- **16:00 - 16:30**  
  Transcriptomics and T3 action in the mouse brain  
  Frédéric Flamant (France)

- **16:30 - 17:00**  
  Transcriptional and genome wide responses to TH in skeletal cell lineages  
  John Howard Duncan Bassett (United Kingdom)

- **17:00 - 17:30**  
  TH and glucocorticoid transcriptional interactions during development  
  Laurent Sachs (France)

---

16:00 - 17:30  
**Room SALLE M**

**SCIENTIFIC Symposium 4**

**INTERMEDIATE** risk thyroid cancer  
Chairs: Francesco Frasca (Italy) and Annick Van Den Bruel (Belgium)

- **16:00 - 16:30**  
  Molecular markers for aggressive behavior in intermediate risk  
  TC Miguel Melo (Portugal)

- **16:30 - 17:00**  
  Pathologic features for unfavorable outcome  
  José Cameselle-Teijeiro (Spain)

- **17:00 - 17:30**  
  Minimally Invasive Treatment Procedures for Thyroid Malignancy  
  Enrico Papini (Italy)
17:30 - 18:10  
**HENRY LE BOEUF**  
**LISSITZKY AWARD**  
Chairs: Leonidas Duntas (Greece)  
and Graham Williams (United Kingdom)

19:30  
**TOWN HALL**  
**WELCOME RECEPTION**
07:00 - 08:00  Room STUDIO
SATELLITE Symposium 6
PROGRESS in Methodology and Assay Comparison

08:00 - 09:30  Room HENRY LE BOEUF
SCIENTIFIC Symposium 5
Joint ETA/ATA and EUGOGO symposium on the medical management of Graves’ Orbitopathy
Chairs: Tomasz Bednarczuk, Poland and Chantal Daumerie, Belgium

08:00 - 08:20  Lelio Baldeschi (Netherlands)
When is enough steroid sufficient? Congestive GO and its treatment

08:20 - 08:40  Luigi Bartalena (Italy)
Role of teprotumumab in the treatment of Graves’ orbitopathy according to EUGOGO guidelines

08:40 - 09:00  Marius Stan (United States)
Treatment according to ETA/ATA consensus statement

09:00 - 09:15  Mario Salvi (Italy)
Ethical dilemmas in GO

08:00 - 09:30  Room SALLE M
SCIENTIFIC Symposium 6
THYROID hormone physiology and function
Chairs: Nadia Schoenmakers (United Kingdom) and Bruno Lapauw (Belgium)

08:00 - 08:30  Balázs Gereben (Hungary)
Mechanisms regulating HPT axis

08:30 - 09:00  Steffen Mayerl (Germany)
Control of TH entry into cells

09:00 - 09:30  Krishna Chatterjee (United Kingdom)
Metabolic consequences of human hyper and hypothyroidism
**ORAL Session 6**

**HYPOTHYROIDISM**

Chairs: Philippe Caron (France) and Ulla Feldt-Rasmussen (Denmark)

**10:00 - 10:12**  
**OP-06-27**  
Evaluation of dried blood spot thyroglobulin as a biomarker for iodine status in pregnant women and newborns.  
*Camilo Fuentes Peña (Belgium)*

**10:12 - 10:24**  
**OP-06-28**  
The optimal ranges of thyroid function based on the risk of cardiovascular disease and mortality: an individual participant data meta-analysis  
*Yanning Xu (Netherlands)*

**10:24 - 10:36**  
**OP-06-29**  
Central hypothyroidism ensuing endonasal transsphenoidal pituitary surgery: the role of a post operative TRH stimulation test  
*Mathieu Claus (Belgium)*

**10:36 - 10:48**  
**OP-06-30**  
Levothyroxine replacement therapy overuse and factors guiding successful treatment discontinuation: short and long-term observation data of a large cohort  
*Sarantis Livadas (Greece)*

**10:48 - 11:00**  
**OP-06-31**  
Does subclinical hypothyroidism add on any symptoms? evidence from a Danish population-based study  
*Allan Carle (Denmark)*

---

**MONDAY**

12.09.2022
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:12</td>
<td>OP-07-32</td>
<td>The micro-RNA content of extracellular vesicles in papillary thyroid cancer: from identification in mouse thyroid tumour to detection in patient plasma</td>
<td>Ophélie Delcorte (Belgium)</td>
</tr>
<tr>
<td>10:12 - 10:24</td>
<td>OP-07-33</td>
<td>Hürthle cell tumors vs oncocytic variants of the follicular cell derived thyroid tumours: a comprehensive analysis based in transcriptome, proteome and CNV profiling</td>
<td>Sule Canberk (Portugal)</td>
</tr>
<tr>
<td>10:24 - 10:36</td>
<td>OP-07-34</td>
<td>CDK4 phosphorylation status and rational use of CDK4/6 inhibitors in advanced thyroid cancers</td>
<td>Jaime M Pita (Belgium)</td>
</tr>
<tr>
<td>10:36 - 10:48</td>
<td>OP-07-35</td>
<td>RET Fusion Genes in a Large Cohort of Papillary Thyroid Carcinomas</td>
<td>Barbora Pekova (Czech Republic)</td>
</tr>
<tr>
<td>10:48 - 11:00</td>
<td>OP-07-36</td>
<td>Loss of tumor cell MHC Class II expression as driver of relapse to dabrafenib and trametinib in mouse BRAF-mutant anaplastic thyroid cancer</td>
<td>Vera Tiedje (United States)</td>
</tr>
</tbody>
</table>
**11:00 - 12:00**

**HENRY LE BOEUF**

**SATELLITE Symposium 7**

**TARGETING Biomarker Driven Advanced Thyroid Cancer Today: Most recent Diagnostic and Treatment Updates**

**12:00 - 13:00**

**POSTER HALL**

**POSTER Session 3**

<table>
<thead>
<tr>
<th>PS3-11-97 – 105</th>
<th>Case reports</th>
<th>Chair: Corin Badiu (Romania)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS3-12-106 – 113</td>
<td>Graves’ Disease 2 and Orbitopathy</td>
<td>Chair: Luigi Bartalena (Italy)</td>
</tr>
<tr>
<td>PS3-13-114 – 122</td>
<td>Pregnancy &amp; Iodine</td>
<td>Chair: Daniel Glinoer (Belgium)</td>
</tr>
<tr>
<td>PS3-14-123 – 132</td>
<td>Thyroid Cancer Clinical 2</td>
<td>Chair: Steen Bonnema (Denmark)</td>
</tr>
<tr>
<td>PS3-15-133 – 141</td>
<td>TC DIAGNOSIS &amp; Treatment</td>
<td>Chair: George Simeakis (Greece)</td>
</tr>
</tbody>
</table>
13:00 - 13:45
Meet the EXPERT
HENRY LE BOEUF
Thyroid disorders induced by checkpoint inhibitors
Alessandro Antonelli (Italy)

13:00 - 13:45
Meet the EXPERT
RECEPTION LOUNGE
Thyrocyte culture and establishment of organoids
Sabine Costagliola (Italy)

13:00 - 13:45
Meet the EXPERT
STUDIO
Systemic effects of TH metabolism in skeletal muscle
Monica Dentice (Italy)

13:00 - 13:45
Meet the EXPERT
SALLE M
Familial Non-MTC
Maria Grazia Castagna (Italy)
13:45 - 14:45  Room SALLE M

**ORAL Session 8**

**BASIC 2**

Chairs: Francoise Miot (Belgium) and Lars Moeller (Germany)

13:45 - 13:57  OP-08-37
Resistance to Thyroid Hormone alpha:
Molecular, Biochemical and Physiological
approach to diagnosis and therapy
_Maura Agostini (United Kingdom)_

13:57 - 14:09  OP-08-38
Brain effects of combined levothyroxine (T4)
and 3-iodothyronamine (T1AM) replacement
therapy in a murine model of hypothyroidism
_Andrea Bertolini (Italy)_

14:09 - 14:21  OP-08-39
Stochastic epigenetic mutations as possible
explanation for phenotypical discordance among
twins with congenital hypothyroidism
_Marina Muzza (Italy)_

14:21 - 14:33  OP-08-40
Disrupted trans-placental thyroid hormone
transport in a human model for MCT8
deficiency
_Zhongli Chen (Netherlands)_

14:33 - 14:45  OP-08-41
Borealin/CDCA8 is necessary for an adequate
thyroid morphogenesis and aging
_Carré Aurore (France)_

**MONDAY**

12.09.2022
13:45 - 14:45

HENRY LE BOEUF

ORAL Session 9

Thyroid Cancer Clinical

Chairs: Maria Grazia Castagna (Italy) and João Jácome De Castro (Portugal)

13:45 - 13:57  
OP-09-42  
Childhood papillary thyroid carcinoma: long-term postoperative outcome and prediction of recurrent disease in 189 patients consecutively treated at the Mayo Clinic during 1936 through 2020  
Ian Hay (United States)

13:57 - 14:09  
OP-09-43  
Novel somatic mutations in sporadic MTC (spMTC); Clinical utility of NGS In precision medicine  
George Simeakis (Greece)

14:09 - 14:21  
OP-09-44  
Dynamic risk stratification in long-term clinical outcome of papillary thyroid cancer patients  
Laura Valerio (Italy)

14:21 - 14:33  
OP-09-45  
The phenotype correlated with RET V804 germline mutation is characterized by the presence of medullary thyroid cancer alone  
Cristina Romei (Italy)

14:33 - 14:45  
OP-09-46  
Interim outcome analysis of prospective ATA recurrence risk (RR) stratification for postoperative treatment and follow up of differentiated thyroid cancer (DTC)  
Xun Yang Hu (Canada)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45 - 15:30</td>
<td>SHORT CALL Abstracts</td>
<td>Room 1</td>
</tr>
<tr>
<td></td>
<td>Chair: Laura Fugazzola, Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SHC-397 Pre-conditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fabiana Pani (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SHC-425 Thyroid hormone stimulates brown fat BCAA metabolism when glucose uptake is impaired</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paul Yen (Singapore)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SHC-398 Clinically-relevant Germline Variants are Common in Children with Non-Medullary Thyroid Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Karin van der Tuin (The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:45</td>
<td>SATELLITE Symposium 8</td>
<td>Room 1</td>
</tr>
<tr>
<td></td>
<td>HYPOTHYROIDISM treatment. Where are we and where are we going?</td>
<td></td>
</tr>
<tr>
<td>16:45 - 17:30</td>
<td>PINCHERA Prize Lecture</td>
<td>Room 1</td>
</tr>
<tr>
<td></td>
<td>Chairs: Graham Williams (United Kingdom) and Leonidas Duntas (Greece)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A journey through signaling, transcription and epigenetic in the thyroid</td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:45</td>
<td>ETA General Assembly</td>
<td>Room 1</td>
</tr>
<tr>
<td>20:00</td>
<td>ETA Network Dinner</td>
<td>VAUDEVILLE THEATER</td>
</tr>
<tr>
<td></td>
<td>REMINISCENCE: Thyroid Research in Belgium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Daniel Glinoer</td>
<td></td>
</tr>
</tbody>
</table>

**MONDAY 12.09.2022**
08:00 - 08:30  Room SALLE M

RESEARCH GRANT 2020 – Winner Presentations

Chair: Tomasz Bednarczuk (Poland)

**T3 and T4, is that all?**

*Layal Chaker (Netherlands)*

**Targeting mitochondrial TERT to overcome therapeutic resistance**

*Paula Soares (Portugal)*

08:30 - 10:30  Room SALLE M

ORAL Session 10

Young Investigator CLINICAL + TRANSLATIONAL

Chairs: Simone De Leo (Italy)

and Rodrigo Moreno-Reyes (Belgium)

08:30 - 08:50  Room SALLE M

**OP-10-47**

Putative protective role of anti-nuclear antibodies in Graves’ orbitopathy

*Giulia Lanzolla (Italy)*

08:50 - 09:10  Room SALLE M

**OP-10-48**

WITHDRAWN

09:10 - 09:30  Room SALLE M

**OP-10-49**

TSH-receptor antibodies among 1,024 early pregnant women in the North Denmark Region: cut-off, prevalence, and follow-up

*Nanna Maria Uldall Torp (Denmark)*

09:30 - 09:50  Room SALLE M

**OP-10-50**

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma

*João Roque (Portugal)*

09:50 - 10:10  Room SALLE M

**OP-10-51**

Hypocalcemia is a frequent and life-threatening effect during Lenvatinib treatment

*Matteo Trevisan (Italy)*

10:10 - 10:30  Room SALLE M

**OP-10-52**

Outcome of sporadic medullary thyroid cancer (MTC) patients with a biochemical persistent disease after initial treatment

*Alessandro Prete (Italy)*
08:30 - 10:30

**Room STUDIO**

**ORAL Session 11**

**Young Investigator BASIC**

Chairs: Barbara Demeneix (France) and Paula Soares (Portugal)

08:30 - 08:50  
**OP-11-53**  
CD3+CD8+CD20+ T cells as a marker of the inflammatory phase in thyroid autoimmune and related polyautoimmune disorders: a pilot study  
*Ilaria Stramazzo* (Italy)

08:50 - 09:10  
**OP-11-54**  
Study of TARget tissue-resident immune cells in Graves’ disease and Orbitopathy (STAR-GO): preliminary findings with a novel extensive immunophenotyping panel  
*Sara Maioli* (Italy)

09:10 - 09:30  
**OP-11-55**  
Role of NADPH oxidase 4 (NOX4) in resistance to metabolic iodine-131 radiotherapy in metastatic thyroid tumors carrying the BRAFV600E mutation  
*Mickaelle Radom* (France)

09:30 - 09:50  
**OP-11-56**  
Focusing on the role of the enigmatic TRa2 isoform in modulation of thyroid hormone action  
*Nina Härting* (Germany)

09:50 - 10:10  
**OP-11-57**  
Monocarboxylate 8 transporter and deiodinase 2 deficiency impairs neurogliogenesis in the adult mouse subventricular zone leading to cellular and functional alterations  
*Víctor Valcárcel-Hernández* (Spain)

10:10 - 10:30  
**OP-11-58**  
Integrated genomic, phenomic, functional and structural mapping of variants in thyroid hormone transporter MCT8  
*Ferdy van Geest* (Netherlands)

**TUESDAY**

13.09.2022
11:00 - 12:00

ORAL Session 12

Nodules and Diagnostic

Chairs: Steen Bonnema (Denmark) and Valeriano Leite (Portugal)

11:00 - 11:12  OP-12-59
Autonomously functioning thyroid nodules present intermediate malignancy risk according to European Thyroid Imaging and Reporting Data System; A comprehensive clinical, cytological and molecular characterization.
Aglaia Kyrilli (Belgium)

11:12 - 11:24  OP-12-60
Population study on thyroid nodule ultrasound (TUS) reports quality with adherence to guidelines
Xun Yang Hu (Canada)

11:24 - 11:36  OP-12-61
Comparison of accuracy of 18F-fluorocholine PET-CT and PET/MR to 99mTc-sestaMIBI for the localization of hyperfunctioning parathyroid tissue in hyperparathyroidism.
Céline Mathey (Belgium)

11:36 - 11:48  OP-12-62
Progressive Diastolic Dysfunction in Survivors of Pediatric Differentiated Thyroid Carcinoma
Antoinette Reichert (Netherlands)

11:48 - 12:00  OP-12-63
Real-world performance of a novel dual-component molecular assay in cytologically indeterminate thyroid nodules: a single institutional experience
Marialuisa Sponziello (Italy)
ORAL Session 13

BASIC 3

Chairs: Sebastian Hönes (Germany) and Gerasimo Sykiotis (Switzerland)

11:00 - 11:12  OP-13-64
Metabolic and neuroinflammatory consequences of hypothyroidism in two mouse strains with different metabolic adaptability capacities, the C57BL/6J and the WSB/EiJ strains
Marie-Stéphanie Clerget-Froidevaux (France)

11:12 - 11:24  OP-13-65
3,3',5-triiodo-L-thyronine and 3,5-diodo-L-thyronine differentially modulate hepatic mitochondrial quality control in hypothyroid rats
Antonia Giacco (Italy)

11:24 - 11:36  OP-13-66
Generation of human thyroid organoids from embryonic stem cells to rescue hypothyroidism
Mirian Romitti (Belgium)

11:36 - 11:48  OP-13-67
A Single Cell Atlas of the T3-responsive Transcriptome during Early Cortical Neurogenesis in Human Cerebral Organoids
Robert Opitz (Germany)

11:48 - 12:00  OP-13-68
WITHDRAWN

TUESDAY
13.09.2022
**SCIENTIFIC Symposium 7**

New avenues for diagnostic and treatment of thyroid cancer

Chairs: Maria-Cristina Burlacu (Belgium) and Gabriella Pellegriti (Italy)

12:10 - 12:40  **Mutations in DICER1 and other microRNA genes in thyroid nodules**  
*Barbara Rivera (Spain)*

12:40 - 13:10  **Role of Tumor Microenvironment in Thyroid Cancer Metastasis**  
*Małgorzata Oczko-Wojciechowska (Poland)*

13:10 - 13:40  **RET rearrangements as druggable targets in papillary thyroid carcinomas**  
*Thomas Musholt (Germany)*

**SCIENTIFIC Symposium 8**

Ageing/Genetics

Chairs: Leonidas Duntas (Greece) and W. Edward Visser (Netherlands)

12:10 - 12:40  **Impact of ageing on TFT**  
*Diana van Heemst (Netherlands)*

12:40 - 13:10  **Treatments of Hypothyroidism**  
*Bernadette Biondi (Italy)*

13:10 - 13:40  **Dio2 polymorphisms clinical implications**  
*Colin Dayan (United Kingdom)*
13:40 - 14:00

ROOM SALLE M

PRIZE CEREMONY and CLOSURE

Chairs: Graham Williams (United Kingdom) and Leonidas Duntas (Greece)
Industry Sponsored Satellite Symposia
SATURDAY, 10.09.
15.30 - 16.30 ETA Industry-sponsored Satellite Symposium 1: ROCHE SALLE M

SUNDAY, 11.09.
07.00 - 08.00 ETA Industry-sponsored Satellite Symposium 2: VINDICO STUDIO
11.00 - 12.00 ETA Industry-sponsored Satellite Symposium 3: MERCK HENRY LE BOEUF
12.00 - 13.00 ETA Industry-sponsored Satellite Symposium 4: EISAI SALLE M
15.00 - 16.00 ETA Industry-sponsored Satellite Symposium 5: IPSEN SALLE M

MONDAY, 12.09.
07.00 - 08.00 ETA Industry-sponsored Satellite Symposium 6: QUIDEL STUDIO
11.00 - 12.00 ETA Industry-sponsored Satellite Symposium 7: LILLY HENRY LE BOEUF
15.45 - 16.45 ETA Industry-sponsored Satellite Symposium 8: IBSA HENRY LE BOEUF
44th Annual ETA Meeting Industry Satellite Symposium

Making treatment decisions for thyroid cancers with oncogenic drivers

Saturday, 10 September 2022, 15:30–16:30 CEST
Salle M, Bozar, Brussels, Belgium

We look forward to welcoming you to this engaging discussion with our expert global panel

Programme

Welcome and introduction
Rossella Elisei – symposium chair

Oncogenic drivers in thyroid cancer
Rossella Elisei

Molecular testing in thyroid cancer: who, when and how?
Jonathan Wadsley

Advancing care for patients with oncogenic drivers
Livia Lamartina

Faculty discussion and Q&A

Expert Panel

Rossella Elisei (chair)
University of Pisa, Italy

Jonathan Wadsley
University of Sheffield, UK

Livia Lamartina
Gustave Roussy, Villejuif, France
CME SATELLITE SYMPOSIUM | For more information visit: ETA2022.com

THYROID EYE DISEASE: Addressing the NEED FOR EARLY INTERVENTION AND COMANAGEMENT

Sunday, 11 September 2022
Bozar
23 Rue Ravenstein | 1000 Brussels | Belgium
Room: Studio

06.45 – 07.00 CET
REGISTRATION

07.00 – 08.00 CET
CME SYMPOSIUM

OVERVIEW
Join us for an exciting, case-based program to learn more about the need for early intervention, comanagement, as well as available treatment options for patients with thyroid eye disease (TED).

Terry J. Smith, MD
ACTIVITY CHAIR
Frederick G.L. Huetwell Professor
Ophthalmology and Visual Sciences
Professor of Internal Medicine
University of Michigan Medical School
Ann Arbor, MI

Raymond S. Douglas, MD, PhD
Professor of Surgery
Division of Ophthalmology
Director, Orbital and Thyroid Eye Disease Program
Cedars-Sinai Medical Center
Los Angeles, CA

George J. Kahaly, MD, PhD
Professor of Medicine and Endocrinology/Metabolism
Department of Medicine
Johannes Gutenberg University Medical Center
Mainz, Germany

This continuing medical education activity is provided by VINDICO medical education®

This activity is supported by an educational grant from Horizon Therapeutics Ireland DAC.

Held in conjunction with ETA European Thyroid Association
AGENDA

07.00 CET  Introduction and Pretest
            Terry J. Smith, MD

07.05 CET  Detecting and Assessing Thyroid Eye Disease
            Terry J. Smith, MD

07.20 CET  Treating Thyroid Eye Disease in the Here and Now
            Raymond S. Douglas, MD, PhD

07.35 CET  TED Case Discussion
            George J. Kahaly, MD, PhD

07.50 CET  Posttest and Question & Answer

08.00 CET  Conclusion

LEARNING OBJECTIVES

Upon successful completion of this activity, participants should be better able to:

- Review evidence-based recommendations regarding the differentiation and assessment of disease activity to aid in earlier diagnosis, classification, and treatment of TED.

- Assess current evidence regarding the efficacy, safety, benefits, and limitations of conventional and new therapies for the treatment of TED.

- Summarize best practices for treatment and referral that can improve the multidisciplinary comanagement of patients with TED.

TARGET AUDIENCE

The intended audience for this activity is endocrinologists, ophthalmologists, and other health care professionals involved in the management of people with TED.

This symposium is intended for registered attendees of ETA Brussels 2022 only. Symposium pre-registration is not required; seating is based on arrival order. ETA Brussels 2022 information can be found at: ETA2022.com.

Questions? Questions@VindicoCME.com

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is designed for AMA PRA Category 1 Credit(s)™ for US physicians only. All non-US physicians should contact their respective Boards for accreditation/credit status.

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.
Merck Satellite Symposium
44th Annual ETA Meeting 2022 Brussels

T3 for hypothyroidism

Sunday, September 11th
11.00 – 12.00 am CEST

AGENDA

Chair and Moderation:
George KAHALY (Germany)

Rationale, basic & clinical data for T3 supplementation
Anne R. Cappola (US)

ETA / ATA / BTA Consensus: Facts, requirements, and planned trials
Colin Dayan (UK)

Practical experience with T3: Dose, daily intake, adverse events, and monitoring
Birte Nygaard (Denmark)
Eisai promotional satellite symposium at the 2022 annual meeting of the European Thyroid Association

JOIN US AS WE DEBATE...

Where does the balance lie in achieving good clinical outcomes and quality of life in RAI-R DTC?

Sunday 11th September 2022 | 12:00 – 13:00 CEST |

Systemic therapy should be reserved for patients with symptomatic disease

- Professor Cosimo Durante
  - University of Rome ‘Sapienza’, Italy

Treatment with systemic therapy should be initiated early to maximise clinical outcomes

- Dr Sophie Lebouleux
  - Hôpitaux Universitaires de Genève, Switzerland

Can we leverage pre-habilitation and AE management strategies to maintain patient QoL while on systemic therapy?

- Professor Cosimo Durante
- Dr Sophie Lebouleux

Q&A and panel discussion

Chaired by Professor Laura Fugazzola, University of Milan, Italy

Eisai products will be discussed at this meeting. Eisai organized and funded this satellite symposium.

EMEA-LENA-22-00110
Date of Preparation: August 2022
NEW DIRECTIONS IN THYROID CANCER: TREATMENT SEQUENCING
WITH INTERACTIVE TUMOUR BOARD

FACULTY:
Laura Fugazzola (Italy)
Michael Kreissl (Germany)
Cosimo Durante (Italy)

Welcome and Introduction
15:00

The evolving landscape: Advances in Thyroid cancer treatment
15:05

Looking to the future in RAI-R DTC
15:20

RAI-R DTC treatment in the real-world setting: An interactive tumour board
15:35
Quidel Satellite Symposium

Monday, September 12, 2022
07:00 - 08:00

Progress in Methodology and Assay Comparison

Antibody functionality and novel developments
George J. Kahaly
Mainz, Germany

Multicenter, single blind, prospective comparison of TSH-R assays
Mark A. Lupo
Sarasota, Florida, USA

Breakfast will be provided!
Targeting Biomarker-Driven
Advanced Thyroid Cancer Today:
Most Recent Diagnostics and Treatment Updates

Symposium Objectives

- Discuss the optimal diagnostic techniques and guidelines to identify actionable biomarker-driven thyroid cancer to support treatment decisions
- Accelerate the translation of clinical evidence into clinical practice for patients with advanced thyroid cancer
- Facilitate the exchange of clinical experience in the management of thyroid cancer

Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Introduction and welcome</td>
<td>Patrick Pauwels, Belgium (Chair)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Laura Fugazzola, Italy (Chair)</td>
</tr>
<tr>
<td>11:05</td>
<td>Tissue testing for actionable biomarkers in patients with advanced thyroid cancer</td>
<td>Patrick Pauwels, Belgium</td>
</tr>
<tr>
<td>11:15</td>
<td>Biomarker-driven thyroid cancer: state of the art treatments of advanced diseases</td>
<td>Sophie Lebouleux, Switzerland</td>
</tr>
<tr>
<td>11:30</td>
<td>Panel discussion</td>
<td>Moderated by Laura Fugazzola</td>
</tr>
<tr>
<td>11:45</td>
<td>Case-based discussion on practical management of thyroid cancer</td>
<td>Robin Peeters, Netherlands</td>
</tr>
<tr>
<td>11:58</td>
<td>Closing remarks</td>
<td>Patrick Pauwels, Belgium</td>
</tr>
</tbody>
</table>
INVI TATION
IBSA Satellite Symposium

Monday, September 12th, 2022
15.45-16.45
Room Henry Le Boeuf
Bozar Brussels
IBSA Satellite Symposium

Hypothyroidism treatment. Where are we and where are we going?

Monday, September 12th, 2022
15.45-16.45

PROGRAM

Chairman: Laszlo Hegedüs (Denmark)

15.45-15.50 Welcome and introduction
Laszlo Hegedüs

15.50-16.15 Thyroid hormone formulations: is their availability a determinator of their use in Europe?
Enrico Papini (Italy)

16.15-16.40 Factors affecting LT4 absorption: which strategies to overcome the barriers?
Pierpaolo Trimboli (Switzerland)

16.40-16.45 Closing remarks
Laszlo Hegedüs
Special thanks for their support goes to

BRUSSELS, a lively city that’s always on the go. It has an incredible wealth of culture, heritage and architecture just waiting to be discovered. Explore its must-see places, museums, exhibitions, quirky corners and vibrant events.
SAVE THE DATE

45th Annual Meeting of the European Thyroid Association

MILAN
9-12 September 2023
Transparency Declaration

The Executive Committee and the Standing Office of the ETA are most grateful to the following ETA Corporate members and all other sponsors for their generous logistical support of the ETA 2022 Annual Meeting

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Amount</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer HealthCare Pharmaceutica Inc.</td>
<td>1500 €</td>
<td>for a placement of a roll-up</td>
</tr>
<tr>
<td>Berlin-Chemie AG</td>
<td>1500 €</td>
<td>for the sponsorship of the Young Investigator Prize</td>
</tr>
<tr>
<td>Eco Microwave</td>
<td>3000 €</td>
<td>for an exhibition space</td>
</tr>
<tr>
<td>Egetis Therapeutics AB</td>
<td>3000 €</td>
<td>for an exhibition space</td>
</tr>
<tr>
<td>Eisai Europe Ltd.</td>
<td>11000 €</td>
<td>for a satellite symposium</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche Ltd.</td>
<td>30000 €</td>
<td>for a satellite symposium</td>
</tr>
<tr>
<td>IBSA Institut Biochimique SA</td>
<td>30000 €</td>
<td>for a satellite symposium</td>
</tr>
<tr>
<td>Ipsen Innovation S.A.S.</td>
<td>30000 €</td>
<td>for a congress symposium</td>
</tr>
<tr>
<td>LCMS</td>
<td>30000 €</td>
<td>for a congress symposium</td>
</tr>
<tr>
<td>Merck KGaA</td>
<td>30000 €</td>
<td>for a satellite symposium</td>
</tr>
<tr>
<td>piur imaging GmbH</td>
<td>3000 €</td>
<td>for an exhibition space</td>
</tr>
<tr>
<td>Quidel</td>
<td>15000 €</td>
<td>for a satellite symposium</td>
</tr>
<tr>
<td>RF Medical Co. Ltd.</td>
<td>3000 €</td>
<td>for an exhibition space</td>
</tr>
<tr>
<td>STARmed Co., Ltd.</td>
<td>4500 €</td>
<td>for an exhibition space</td>
</tr>
<tr>
<td>Vindico Medical Education</td>
<td>15000 €</td>
<td>for a congress symposium</td>
</tr>
<tr>
<td>Canon Medical Systems</td>
<td>15000 €</td>
<td>Provision of ultrasound machines</td>
</tr>
<tr>
<td>Belgium NV/SA</td>
<td></td>
<td>Provision of ultrasound machines</td>
</tr>
</tbody>
</table>